Ken Bartizal, Chief Development Officer at Trius Therapeutics Inc (TSRX), sold 12,000 shares at $7.93 ($95K) on 2013-05-24, disclosed to the SEC on 2013-05-28.
Scheduled sale ($95k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TSRX | SELL | 2013-05-28 | $94K | — | Filing → |
| TSRX | SELL | 2011-11-18 | $13K | — | Filing → |